Reviewed by Michael Gill, B. Sc.
1 Postherpetic Neuralgia Clinical Trials Near Me
Top Hospitals for Postherpetic Neuralgia Clinical Trials
Image of Lexicon Investigational Site in Arizona.
Lexicon Investigational Site
Scottsdale
1Active Trials
1All Time Trials for Postherpetic Neuralgia
2020First Postherpetic Neuralgia Trial
Image of Lexicon Investigational Site in Arizona.
Lexicon Investigational Site
Tucson
1Active Trials
1All Time Trials for Postherpetic Neuralgia
2020First Postherpetic Neuralgia Trial
Top Cities for Postherpetic Neuralgia Clinical Trials
Image of Miami in Florida.
Miami
2Active Trials
Lexicon Investigational SiteTop Active Site
Image of Scottsdale in Arizona.
Scottsdale
1Active Trials
Lexicon Investigational SiteTop Active Site
Postherpetic Neuralgia Clinical Trials by Phase of Trial
Phase 2 Postherpetic Neuralgia Clinical Trials
1Active Postherpetic Neuralgia Clinical Trials
1Number of Unique Treatments
21Number of Active Locations
Postherpetic Neuralgia Clinical Trials by Age Group
18+ Postherpetic Neuralgia Clinical Trials
1Active Postherpetic Neuralgia Clinical Trials
Most Recent Postherpetic Neuralgia Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Top Treatments for Postherpetic Neuralgia Clinical Trials
Treatment Name
Active Postherpetic Neuralgia Clinical Trials
All Time Trials for Postherpetic Neuralgia
First Recorded Postherpetic Neuralgia Trial
LX9211
1
1
2020

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 29th, 2021

Last Reviewed: October 15th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Luo G, Chen L, Kostich WA, Hamman B, Allen J, Easton A, Bourin C, Gulianello M, Lippy J, Nara S, Maishal TK, Thiyagarajan K, Jalagam P, Pattipati SN, Dandapani K, Dokania M, Vattikundala P, Sharma V, Elavazhagan S, Verma MK, Das ML, Wagh S, Balakrishnan A, Johnson BM, Santone KS, Thalody G, Denton R, Saminathan H, Holenarsipur VK, Kumar A, Rao A, Putlur SP, Sarvasiddhi SK, Shankar G, Louis JV, Ramarao M, Conway CM, Li YW, Pieschl R, Tian Y, Hong Y, Ditta J, Mathur A, Li J, Smith D, Pawluczyk J, Sun D, Yip S, Wu DR, Vetrichelvan M, Gupta A, Wilson A, Gopinathan S, Wason S, Bristow L, Albright CF, Bronson JJ, Macor JE, Dzierba CD. Discovery of (S)-1-((2',6-Bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2- amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain. J Med Chem. 2022 Mar 24;65(6):4457-4480. doi: 10.1021/acs.jmedchem.1c02131. Epub 2022 Mar 8. https://pubmed.ncbi.nlm.nih.gov/35257579